title: Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study.
abstract: OBJECTIVE
  This study with 31 obese binge eaters (body mass index [BMI] 39.5+/-8.6 kg/m(2) [SD]) was designed to assess whether diet counseling with psychological support and imipramine or placebo has an effect on the frequency of binge eating, body weight, and depression during an 8-week treatment phase. This was followed by an open medication-free phase of 6 months of continuous diet counseling with psychological support.
  
  
  METHODS
  Randomized double-blind placebo-controlled study of 8 weeks followed by an open phase of 6 months. Patients were evaluated in medical visits by a semistructured videotaped interview, psychometric questionnaires, and hematochemical parameters.
  
  
  RESULTS
  From Week 0 to 8, a significant reduction in binge frequency occurred in both treatment conditions (7.1+/-4.1 to 2.8+/-3.0 binges per week [imipramine] vs. 7.1+/-4.1 to 5.4+/-5.1 [placebo], p<.01). Patients on imipramine lost -2.2+/-1.8 kg compared to placebo-treated subjects (+0.2+/-3.3 kg, p<.001). On follow-up, only the patients initially treated with imipramine continued to lose weight (-5.1+/-2.8 kg [imipramine] vs. 2.2+/-6.8 kg [placebo], p<.001 [differences to Week 0]). While both treatment conditions were associated with significant improvements on a rater's measure of depressive symptoms (Hamilton Depression Scale) at Week 8, only the patients treated with imipramine still showed a significant improvement at Week 32. Scores on the Self Depression Rating Scale did not show a group difference but a significant reduction at Weeks 8 and 32, compared to baseline.
  
  
  CONCLUSIONS
  These results suggest that adding low-dose imipramine to diet counseling with psychological support helps patients losing weight even for at least 6 months off medication. The effect might include a psychological priming of weight loss during the double-blind phase that continues at least for half a year after stopping the drug.
authors.affiliation: Unit for Psychosomatic and Psychosocial Medicine, University of Berne, Berne, Switzerland. laederach@insel.ch
authors.forename: K
authors.initials: K
authors.lastname: Laederach-Hofmann
authors.forename: C
authors.initials: C
authors.lastname: Graf
authors.forename: F
authors.initials: F
authors.lastname: Horber
authors.forename: K
authors.initials: K
authors.lastname: Lippuner
authors.forename: S
authors.initials: S
authors.lastname: Lederer
authors.forename: R
authors.initials: R
authors.lastname: Michel
authors.forename: M
authors.initials: M
authors.lastname: Schneider
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000328:Adult; D003376:Counseling; D003863:Depression / Q000175:diagnosis / Q000523:psychology; D004311:Double-Blind Method; D002149:Energy Intake; D001068:Feeding and Eating Disorders / Q000628:therapy*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000178:diet therapy* / Q000188:drug therapy*; D011613:Psychotherapy / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D007099:Imipramine